Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72205-0063-01 72205-0063 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
72205-0062-01 72205-0062 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
72205-0061-01 72205-0061 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
71288-0158-96 71288-0158 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Oct. 23, 2020 In Use
71288-0132-90 71288-0132 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 28, 2021 In Use
71288-0119-20 71288-0119 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 2, 2021 In Use
72237-0104-01 72237-0104 selinexor XPOVIO 60.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
71332-0005-01 71332-0005 Olutasidenib REZLIDHIA 150.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Dec. 1, 2022 In Use
16571-0817-02 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-51 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0817-41 16571-0817 Temozolomide TEMOZOLOMIDE 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-02 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-51 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-41 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-02 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-51 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0819-41 16571-0819 Temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-02 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-51 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0820-41 16571-0820 Temozolomide TEMOZOLOMIDE 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-02 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-51 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0821-41 16571-0821 Temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
43598-0045-28 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0045-63 43598-0045 SUNITINIB MALATE SUNITINIB MALATE 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0046-28 43598-0046 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0046-63 43598-0046 SUNITINIB MALATE SUNITINIB MALATE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0047-28 43598-0047 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0047-63 43598-0047 SUNITINIB MALATE SUNITINIB MALATE 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0048-28 43598-0048 SUNITINIB MALATE SUNITINIB MALATE 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
43598-0048-63 43598-0048 SUNITINIB MALATE SUNITINIB MALATE 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Nov. 30, 2022 In Use
16714-0578-01 16714-0578 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 18, 2022 In Use
16729-0250-03 16729-0250 Bendamustine hydrochloride Bendamustine hydrochloride 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
16729-0251-05 16729-0251 Bendamustine hydrochloride Bendamustine hydrochloride 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
62332-0620-05 62332-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0621-17 62332-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0622-50 62332-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
71225-0120-01 71225-0120 BENDAMUSTINE HYDROCHLORIDE VIVIMUSTA 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
50419-0393-03 50419-0393 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Dec. 6, 2022 In Use
25021-0235-50 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0235-51 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 15, 2022 In Use
68083-0502-01 68083-0502 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Nov. 22, 2022 In Use
43598-0171-11 43598-0171 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Nov. 1, 2022 In Use
46708-0618-31 46708-0618 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
46708-0619-31 46708-0619 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
49884-0128-91 49884-0128 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Nov. 29, 2022 In Use
62332-0618-31 62332-0618 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
62332-0619-31 62332-0619 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
65219-0550-01 65219-0550 Pralatrexate Pralatrexate 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
65219-0552-02 65219-0552 Pralatrexate Pralatrexate 40.0 mg/2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
00378-7131-93 00378-7131 erlotinib hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
63629-1472-01 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2014 In Use
63629-1472-02 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Jan. 16, 2008 In Use
63629-1472-03 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral April 19, 2010 In Use
63629-1472-04 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral July 19, 2010 In Use
63629-1472-05 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 11, 2012 In Use
63629-1472-06 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 26, 2019 In Use
63629-1472-07 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Sept. 20, 2021 In Use
63629-1472-08 63629-1472 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Sept. 20, 2021 In Use
71288-0100-05 71288-0100 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 19, 2017 In Use
71288-0100-15 71288-0100 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 19, 2017 In Use
71288-0100-45 71288-0100 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 19, 2017 In Use
71288-0100-51 71288-0100 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 19, 2017 In Use
00378-7132-93 00378-7132 erlotinib hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
00378-7133-93 00378-7133 erlotinib hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
67457-0455-00 67457-0455 Cytarabine Cytarabine 100.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec. 14, 2011 No Longer Used
67457-0455-52 67457-0455 Cytarabine Cytarabine 100.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec. 14, 2011 Oct. 31, 2022 No Longer Used
00517-0920-08 00517-0920 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous April 1, 2017 In Use
00781-3296-80 00781-3296 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 1, 2020 In Use
50268-0427-12 50268-0427 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 24, 2017 In Use
62559-0925-51 62559-0925 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 Oct. 31, 2022 No Longer Used
65219-0160-10 65219-0160 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Nov. 11, 2019 In Use
69097-0274-37 69097-0274 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 10, 2017 In Use
69097-0353-78 69097-0353 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 10, 2017 In Use
00003-0830-50 00003-0830 Hydroxyurea Hydrea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral June 1, 2009 March 31, 2025 In Use
70771-1058-00 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-01 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-02 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-03 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-05 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-07 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
70771-1058-09 70771-1058 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 9, 2017 In Use
69448-0005-12 69448-0005 Carboplatin Paraplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 12, 2020 Aug. 31, 2023 In Use
69448-0005-31 69448-0005 Carboplatin Paraplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 12, 2020 Nov. 30, 2022 In Use
69448-0005-33 69448-0005 Carboplatin Paraplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 12, 2020 Nov. 30, 2022 In Use
69448-0005-34 69448-0005 Carboplatin Paraplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Feb. 12, 2020 July 31, 2023 In Use
69448-0005-38 69448-0005 Carboplatin Paraplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 17, 2020 In Use
00378-3096-85 00378-3096 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00378-3098-85 00378-3098 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00781-3253-94 00781-3253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 16, 2013 Feb. 28, 2025 In Use
16729-0131-30 16729-0131 FLUDARABINE FLUDARABINE PHOSPHATE 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 22, 2022 In Use
71288-0112-90 71288-0112 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 30, 2019 April 30, 2025 In Use
00480-5425-89 00480-5425 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Jan. 3, 2023 In Use
10019-0079-01 10019-0079 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
55150-0393-01 55150-0393 AZACITIDINE AZACITIDINE 100.0 mg/4mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan. 3, 2023 In Use
61703-0124-40 61703-0124 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Jan. 9, 2023 In Use
70518-3615-00 70518-3615 HYDROXYUREA HYDROXYUREA 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jan. 10, 2023 In Use
71288-0145-10 71288-0145 Pemetrexed disodium Pemetrexed 100.0 mg/4.2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0146-50 71288-0146 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0147-50 71288-0147 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use

Found 10,000 results in 6 millisecondsExport these results